Serum collagen markers and heart failure

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 12, Issue 1, 2012, Pages 51-55

  Lijnen, P J ^a   Maharani, T ^b   Finahari, N ^b   Prihadi, J S ^a  

^a KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

^b BRAWIJAYA UNIVERSITY   (Indonesia)

Author keywords

Biomarkers; Collagen; Heart failure; Myocardial fibrosis

Indexed keywords

AMINO TERMINAL PROPEPTIDE COLLAGEN TYPE I; AMINO TERMINAL PROPEPTIDE COLLAGEN TYPE III; BIOLOGICAL MARKER; CARBOXY TERMINAL PROPEPTIDE COLLAGEN TYPE I; CARBOXY TERMINAL PROPEPTIDE COLLAGEN TYPE III; COLLAGEN DERIVATIVE; PROCOLLAGEN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; BLOOD LEVEL; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC PROCEDURE; DIASTOLIC HEART FAILURE; DISEASE COURSE; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; COLLAGEN; HEART FAILURE; HUMANS;

EID: 84867521714     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152912801823147     Document Type: Review

References (27)

1. Eghbali, M.; Czaja, M.J.; Zeydel, M.; Weiner, Fr.; Zern, M.A.; Seifter, S.; Blumenfefd, O.O. Colllagen chain mRNAs in isolated heart cells from young and adult rats. J. Mol. Cell. Cardiol., 1988, 20, 267-276.
2. 1. Mol. Gen. Metab., 2000, 71, 418-435.
3. Alla, F.; Kearney-Schwartz, A.; Radauceanu, A.; Das Dores, S.; Dousset, B.; Zannad, F. Early changes in serum markers of cardiac extracellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur. J. Heart Fail., 2006, 8, 147-153.
4. Barasch, E.; Gottdiener, J.S.; Aurigemma, G.; Kitzman, D.W.; Han, J.; Kop, W.J.; Tracy, R.P. Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study. Circ. Heart Fail., 2009, 2, 303-310.
5. Biolo, A.; Rohde, L.E.; Goldraich, L.A.; Mascarenhas, M.; Palombini, D.V.; Clausell, N. Serum procollagen type III is associated with elevated right-sided filling pressures in stable outpatients with congestive heart failure. Biomarkers, 2009, 14, 438-442.
6. Cicoira, M.; Rossi, A.; Bonapace, S.; Zanolla, L.; Golia, G.; Franceschini, L.; Caruso, B.; Marino, P.N.; Zardini, P. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J. Card. Fail., 2004, 10, 403-411.
7. Martos, R.; Baugh, J.; Ledwidge, M.; O'Loughlin, C.; Conlon, C.; Patle, A.; Donelly, S.C.; McDonald, K. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation, 2007, 115, 888-895.
8. Plaksej, R.; Kosmala, W.; Frantz, S.; Herrmann, S.; Niemann, M.; Störk, S.; Wachter, R.; Angermann, C.E.; Ertl, G.; Bijnens, B.; Weidermann, F. Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. J. Hypertens., 2009, 27, 2483-2491.
9. Zannad, F.; Alla, F.; Dousset, B.; Perez, A.; Pitt, B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation, 2000, 102, 2700-2706.
10. Zile, M.R.; DeSantis, S.M.; Baica, C.F.; Stroud, R.E.; Thompson, S.B.; McClure, C.D.; Mehurg, S.M.; Spinale, F.G. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ. Heart Fail., 2011, 4, 246-256.
11. Klappacher, G.; Franzen, P.; Haab, D.; Mehrabi, M.; Binder, M.; Plesch, K.; Pacher, R.; Grimm, M.; Pribill, I.; Eichler, H.G. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and inpact on diagnosis and prognosis. Am. J. Cardiol., 1995, 75, 913-918.
12. Sato, Y.; Kataoka, K.; Matsumori, A.; Sasayama, S.; Yamada, T.; Ito, H.; Takatsu, Y. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart, 1997, 78, 505-508.
13. Lombardi, R.; Betocchi, S., Losi, M.A.; Tocchetti, C.G.; Aversa, M.; Miranda, M.; D'Alessndro, G.; Cacaca, A.; Chiampi, Q.; Chiarello, M. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation, 2003,108, 1455-1460.
14. Poulsen, S.H.; Host, N.B.; Jensen, S.E.; Egstrup, K. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation, 2000, 101, 1527-1532.
15. Gonzalez, A.; Lopez, B.; Querejeta, R.; Zubillaga, E.; Echeverria, T.; Diez, J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension, 2010, 55, 1418-1424.
16. Querejeta, R.; Lopez, B.; Gonzalez, A.; Sanchez, E.; Larman, M.; Ubago, J.L.M.; Diez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation, 2004, 110, 1263-1268.
17. Querejeta, R.; Varo, N.; Lopez, B.; Larman, M.; Artinano, E.; Etayo, J.C.; Diez J. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart failure. Circulation, 2000, 101, 1729-1733.
18. Diez, J.; Querejeta, R.; Lopez, B.; Gonzalez, A.; Larman, M.; Ubago, M.J.L. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation, 2002, 105, 2512-2517.
19. Lopez, B.; Querejeta, R.; Gonzalez, A.; Sanchez, E.; Larman, M.; Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. Cardiol., 2004, 43, 2028-2035.
20. Schartzkopff, B.; Fassbach, M.; Pelzer, B.; Brehm, M.; Strauer, B.E. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eu. J. Heart Fail., 2002, 4, 439-404.
21. Kitahara, T.; Takeishi, Y.; Arimoto, T.; Nüzeki, T.; Koyama, Y.; Sasaki, T.; Suzuki, S.; Nozaki, N.; Hirono, O.; Nitaka, J.; Watanabe, T.; Kubata, I. Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Circ. J., 2007, 71, 929-935.
22. Manhenke, C.; Orn, S.; Squire, I.; Radauceanu, A.; Alla, F.; Zannad, F.; Dickstein, K. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int. J. Cardiol., 2011, 150, 277-282.
23. Diez, J.; Laviades, C. Monitoring fibrillar collagen turnover in hypertensive heart disease. Cardiovasc. Res., 1997, 35, 202-205.
24. Ristelli, J.; Ristelli, I. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J. Hepatol., 1995, 2, 77-81.
25. Cornelissen, V.A.; Fagard, R.; Lijnen, P. Serum collagen-derived peptides are unaffected by physical training in older sedentary subjects. J. Sci. Med. Sports, 2010, 13, 424-428.
26. de Jong, S.; van Veen, T.A.B.; de Bakker, J.M.T.; Vos, M.A.; van Rijen, H.V.M. Biomarkers of myocardial fibrosis. J. Cardiovasc. Pharmacol., 2011, 57, 522-535.
27. Moore, L.; Fan, D.; Basu, R., Kandalam, R.; Kassiri, Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail. Rev., 2011, June 30 (Epub ahead of print).